

Access to Healthcare

1. [Dr Jitendra Singh calls for indigenous healthcare strategies](#) – Business Standard
[Click here to read Indian Express story](#)
1. [Major success in health sector](#) - Deccan Herald
2. [Healthcare Policy- Accommodate other pathy medicos: Nadda to allopathic doctors](#) - Indian Express

Others

1. [Counterfeit goods real challenge to 'Make in India': Report](#) - The Economic Times
 2. [How faster USFDA nods will help Indian generic drug makers](#) - The Economic Times
-

Access to Healthcare

1. [Dr Jitendra Singh calls for indigenous healthcare strategies](#) – Business Standard
The Union Minister of State (Independent Charge) for Development of North Eastern Region (DoNER), MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr. Jitendra Singh called for indigenous or, as he put it, Make in India healthcare strategies which could optimally address the healthcare issues from Indian perspective and in Indian conditions. While on the one hand, disorders like Diabetes and heart disease, which were hitherto confined to urban population, are now also on the rise in rural areas, on the other hand, the access to modern modalities of treatment are confined only to cities or big towns as a result of which, 70% of rural population gets access only to 1/3rd of hospitalization facilities and over 600 million people in the country are deprived of access to affordable healthcare.
2. [Major success in health sector](#) - Deccan Herald
The announcement that India has eliminated maternal and neonatal tetanus (MNT) marks a major public health achievement. Prime Minister Narendra Modi made the announcement last week and the World Health Organisation (WHO) finally declared the country free of the health problem months before the target date set in December this year. MNT used to be a major killer of newborn infants and posed a threat to the life and health of mothers too. About two lakh children used to die of tetanus till a few decades ago but the number of casualties has been progressively coming down after the anti-tetanus programme was launched in 2003 as a public-private initiative with support from the WHO, Unicef and other agencies. Neonatal tetanus deaths result from unhygienic delivery practices and inadequate umbilical cord care. These in turn had much to do with lack of awareness of the need for institutional deliveries and of the facilities for them.
3. [Healthcare Policy- Accommodate other pathy medicos: Nadda to allopathic doctors](#) - Indian Express
Union Health Minister J P Nadda on Monday called upon allopathic doctors to accommodate doctors from other disciplines to improve healthcare and meet the shortage of doctors in the country. Addressing a gathering of deans of government medical colleges and private doctors at the concluding session of Vision Aarogyam — 2020 organised by the Vaidakiya Vikas Manch, he said, “We need to keep an open mind and each pathy has to be respected.” He announced that the national health policy would be declared soon and the ministry has invited experts to suggest various measures that would help strike a balance between primary, secondary and tertiary healthcare.

Others

1. [Counterfeit goods real challenge to 'Make in India': Report](#) - The Economic Times
Production of low-quality counterfeit goods has the potential to significantly undermine the 'Make in India' programme that seeks to establish the country as a global manufacturing hub, a report has said. The counterfeit market is growing at a rate of 44 per cent per annum and has touched Rs 1.05 lakh crore in size in 2014, according to 'Sell SMART' report by industry body FICCI and consultancy firm KPMG. As a consequence, since 2010, India has been on the US' `Priority Watch of countries more exposed to IPR (intellectual property rights) violations globally, it said.
2. [How faster USFDA nods will help Indian generic drug makers](#) - The Economic Times
A long spell of sluggish approvals for generic drugs in the US may be nearing an end with early signs of a rebound. A backlog of as many as 4,000 pending applications at the US Food and Drug Administration (USFDA), of which a fourth is estimated to have been filed by Indian firms, is awaiting clearance. Fortunes of generic drug makers to a great extent hinges on their approval timelines. Experts say going by the current run rate, the FDA may clear at least 470 such products this year, a sharp uptick from 409 approvals in 2014.